Realm Therapeutics (NASDAQ:RLM/AIM:RLM) is a company dedicated to the discovery and development of novel therapeutics that improve the health of adults and children.
The Company has a proprietary technology platform of stabilized high concentration hypochlorous acid (HOCl), including an FDA 510(k)-cleared anti-itch hydrogel, previously marketed as Aurstat™, and indicated for the management and relief of pain, burning and itching experienced with various dermatoses, including atopic dermatitis, allergic contact dermatitis and radiation dermatitis and a royalty stream from the Vashe® Wound care portfolio of products out-licensed to a third party.
Realm is currently exploring strategic alternatives, which may include: an acquisition of another company; acquisitions or in-licensing of products, product candidates, technologies or other assets; the licensing or sale of all, or substantially all of the assets of the Company; a strategic merger or other business combination; or another transaction between Realm and a third party.
